Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
David Holtzman
Washington University, Department: Neurology
Should you be removed from our database? Contact us at [email protected]. Read more below.
Eli Lilly
Payment for services (e.g., consulting fees, honoraria, paid authorship)
Based on WU’s Research COI Policy and the Procedures for Determining and Managing Research Financial Conflicts of Interests, the CIRC determined Dr. Holtzman’s personal financial relationship with Eli Lilly, related to the above referenced research, creates a financial conflict of interest due to the following reasons:
• Eli Lilly licenses the intellectual property being evaluated in the research.
• The research is supported by Eli Lilly.
• The research could directly benefit Eli Lilly and may affect the value of his personal financial interest(s).
• As a member of the Therapy Evaluation Committee (TEC), he could influence decisions made about the design of the study.
While the CIRC determined Dr. Holtzman’s have a financial conflict of interest, it concluded adequate protections are in place for the human research participants, and sufficient mechanisms exist to ensure the objectivity and integrity of the research, based on the following reasons:
• Dr. Holtzman is uniquely qualified due to his background, experience and expertise, and the research could not be conducted as safely or effectively without his involvement.
• Dr. Holtzman has limited his involvement in the research, serving only as scientific consultant and advisor, and will have no role in the clinical studies being performed as part of this research.
• Additionally, a plan has been developed to mitigate his financial conflict of interest, which is outlined below.
Dominantly Inherited Alzheimer's Network Trials Unit - Adaptive Prevention Trial
The proposed grant will initiate a phase 3 cognitive end-point prevention trial of an anti-amyloid beta drug in individuals with known causative mutations for dominantly inherited Alzheimer?s disease (AD). Dominantly inherited AD is rare and the symptoms and brain changes are similar to those observed in the more common late-onset sporadic AD. The results of the trial may lead to approval and registration of a drug for the prevention of dominantly inherited AD.
Filed on October 21, 2015.
Tell us what you know about David Holtzman's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “David Holtzman”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| David Holtzman | Washington University | Conflict of Interest | C2N Diagnostics | Value cannot be readily determined |
| David Holtzman | Washington University | Conflict of Interest | C2N Therapeutics | $20,000 - $39,999 |
| David Holtzman | Washington University | Conflict of Interest | Denali Therapeutics | Value cannot be readily determined |
| David Holtzman | Washington University | Conflict of Interest | C2N Diagnostics | $20,000 - $39,999 |
| David Holtzman | Ut Southwestern Medical Center | Conflict of Interest | C2N Diagnostics | Value cannot be readily determined |
| David Holtzman | Washington University | Conflict of Interest | Denali Therapeutics | $10,000 - $19,999 |
| David Holtzman | Washington University | Conflict of Interest | Denali Therapeutics | Value cannot be readily determined |
| David Holtzman | Washington University | Conflict of Interest | Eli Lilly and Company | $0 - $4,999 |
| David Holtzman | Ut Southwestern Medical Center | Conflict of Interest | C2N Diagnostics | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.